Clearbridge Health Ltd. (1H3) AI Stock Analysis

• Market Cap: €12.89M
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): -0.05
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: SG
• Employees: 128
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): >-0.01
• Shares Outstanding: 4,295,821,000
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: <0.01
• Price to Book (P/B): 0.30
• Price to Sales (P/S): 0.28
• P/FCF Ratio: -1.31
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 37 Underperform
• Price Target: S$0.00 ▼(-100.00% Downside)

Clearbridge Health Ltd. is currently facing significant financial difficulties, with ongoing losses and negative cash flows being the most critical issues. The lack of technical and valuation data further complicates the assessment, resulting in a low overall stock score. Immediate attention to financial performance is necessary to improve the company's outlook.

Clearbridge Health Ltd. Business Overview & Revenue Model

Company Description

Clearbridge Health Ltd. (1H3) is a healthcare company focused on providing advanced diagnostics and innovative solutions in the field of personalized medicine. The company operates primarily within the biotechnology and healthcare sectors, offering a range of products and services that include genetic testing, biomarker analysis, and health management solutions. Clearbridge aims to improve patient outcomes through early detection and targeted treatment options, leveraging cutting-edge technology and a strong research foundation.

How the Company Makes Money

Clearbridge Health Ltd. generates revenue through multiple streams, primarily by offering diagnostic testing services to healthcare providers and institutions. This includes the sale of genetic tests, which are used for early detection of diseases and personalized treatment plans. The company may also engage in partnerships with pharmaceutical companies and research institutions to provide insights and data that can enhance drug development processes. Additionally, licensing agreements for proprietary technology and tools used in diagnostics can contribute to their earnings. The integration of services into healthcare systems and collaborations with payers for reimbursement models further support their revenue generation.

Clearbridge Health Ltd. Financial Statement Overview

Summary

Clearbridge Health Ltd. is facing significant financial challenges, with ongoing losses and negative cash flows. Despite a stable gross profit margin and moderate debt level, profitability and cash flow generation remain weak, necessitating urgent improvements.

Income Statement

Clearbridge Health Ltd. has experienced a decline in revenue over the past few years, with a slight recovery in the most recent period. However, the company continues to face significant profitability challenges, as evidenced by negative net profit margins and EBIT margins. The gross profit margin remains relatively stable, but the overall financial performance is hindered by substantial operating losses.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio, indicating a manageable level of leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio suggests a reasonable level of equity financing, but the company's financial stability is compromised by persistent negative returns.

Cash Flow

Clearbridge Health Ltd. has struggled with negative operating and free cash flows, although there is a slight improvement in free cash flow relative to net income. The company faces challenges in generating sufficient cash flow to cover its operational needs, which poses a risk to its financial health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.29M	9.90M	10.41M	16.41M	11.44M	36.26M
Gross Profit	5.12M	4.78M	5.13M	9.58M	6.36M	13.81M
EBITDA	-2.10M	-2.06M	-32.17M	-7.63M	-7.65M	168.00K
Net Income	-2.55M	-3.61M	-32.20M	-11.14M	-19.97M	615.00K
Balance Sheet
Total Assets	18.08M	21.22M	23.92M	58.18M	82.72M	96.99M
Cash, Cash Equivalents and Short-Term Investments	982.00K	3.17M	4.48M	6.05M	14.55M	14.41M
Total Debt	1.45M	6.24M	7.64M	7.47M	12.74M	20.43M
Total Liabilities	4.16M	10.17M	10.64M	12.51M	25.41M	37.04M
Stockholders Equity	12.21M	9.21M	10.19M	42.32M	52.21M	60.45M
Cash Flow
Free Cash Flow	-1.24M	-2.10M	-4.12M	-2.67M	-3.83M	1.53M
Operating Cash Flow	-1.15M	-1.93M	-3.57M	-1.98M	-2.99M	2.61M
Investing Cash Flow	100.00K	1.18M	3.07M	-1.08M	1.18M	-903.00K
Financing Cash Flow	455.00K	266.00K	-1.88M	-2.56M	2.46M	-1.02M

Clearbridge Health Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OTX	―	S$31.85M	11.21	17.26%	7.30%	1.81%	174.36%
1B1	―	S$52.29M	6.19	47.36%	3.47%	1.58%	115.29%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1H3	―	€12.89M	―	-137.86%	―	―	―

Clearbridge Health Ltd. Corporate Events

Clearbridge Health Extends Convertible Bond Maturity Date

Clearbridge Health Limited has announced an extension of the maturity date for its convertible bonds from October 2025 to October 2026. This decision was made to address current challenges faced by the issuer in managing SAM Labs and CBMA, with the belief that the issuer is best positioned to handle these affairs in Indonesia. The extension is seen as beneficial for the group, allowing more effective exercise of rights under the bonds once challenges are resolved.

Clearbridge Health Secures S$1.98 Million in Strategic Placement

Clearbridge Health Limited has successfully raised S$1.98 million through a placement of 990,000,000 new ordinary shares, attracting high-profile investors such as Asdew Acquisitions, Azure Capital, and Ramesh Chandiramani. The funds will be used for general working capital and to seize business opportunities that align with the company’s strategic growth objectives, enhancing its competitiveness and shareholder value.